ArticleOncotarget2016
EFEMP1 promotes ovarian cancer cell growth, invasion and metastasis via activated the AKT pathway.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Subtype Characterization of Ovarian Cancer Cell Lines Using Machine Learning and Network Analysis: A Pilot Study.Cancers · 2025Article
- Impact of Static Myoblast Loading on Protein Secretion Linked to Tenocyte Migration.Journal of proteome research · 2025Article
- Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer.Open medicine (Warsaw, Poland) · 2025Article
- A Comparative Analysis of Naïve Exosomes and Enhanced Exosomes with a Focus on the Treatment Potential in Ovarian Disorders.Journal of personalized medicine · 2024Article
- A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study.British journal of cancer · 2023Article
- Retraction Note: Fibulin-3 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition and activating the Wnt/β-catenin signaling pathway.Scientific reports · 2023Article
- EFEMP1 binds to STEAP1 to promote osteosarcoma proliferation and invasion via the Wnt/β-catenin and TGF-β/Smad2/3 signal pathways.Journal of bone oncology · 2022Article
- Article
- Applications of Multi-omics Approaches for Exploring the Molecular Mechanism of Ovarian Carcinogenesis.Frontiers in oncology · 2021Review
- miR-9-Mediated Inhibition ofCells · 2020Article
- Identification of core genes in the progression of endometrial cancer and cancer cell-derived exosomes by an integrative analysis.Scientific reports · 2020Article
- Article
- Molecular signature of different lesion types in the brain white matter of patients with progressive multiple sclerosis.Acta neuropathologica communications · 2019Article
- Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) suppressed the growth of hepatocellular carcinoma cells by promoting Semaphorin 3B(SEMA3B).Cancer medicine · 2019Article
- Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA Expression.Cancers · 2019Article
- EFEMP2 Inhibits Breast Cancer Invasion And Metastasis In Vitro And In Vivo.OncoTargets and therapy · 2019Article
- Hernia and Cancer: The Points Where the Roads Intersect.Frontiers in surgery · 2019Review
- Mapping the O-glycoproteome using site-specific extraction of O-linked glycopeptides (EXoO).Molecular systems biology · 2018Article
- Fibulin-3 knockdown inhibits cervical cancer cell growth and metastasis in vitro and in vivo.Scientific reports · 2018Article
- Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EFEMP1, a kind of extracellular matrix (ECM) protein, has been suggested to correlate with the development of different types of carcinoma. However, its functions in ovarian cancer remain unclear. In our study, we performed cDNA microarray analysis and identified EFEMP1 dramatically elevated in the highly invasive subclone, compared with the low invasive subclone. Lentivirus transfection experiments were constructed afterwards. The results demonstrated that knockdown of EFEMP1 significantly inhibited ovarian cancer cell proliferation and induced cell cycle arrest at the G1/G0 phase. We also found that decreased the activity of phospho-AKT could suppress cell invasion and metastasis. Meanwhile, the increased phospho-AKT activity induced by the overexpression of EFEMP1 had significantly enhanced the abilities of ovarian cancer cells to invade and migrate. In addition, the vivo nude mice model confirmed that EFEMP1 was tightly correlated with the development of tumor. The results of RT2 Profiler EMT PCR array further indicated that decreased EFEMP1 suppressed epithelial-to-mesenchymal transition (EMT). Collectively, by activating AKT signaling pathway, EFEMP1 contributed to ovarian cancer invasion and metastasis as a positive regulator. Overall, EFEMP1 had showed the potential use in the development of new therapeutic strategies for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.